Merck and Eisai report failed kidney cancer drug trial results

April 21, 2026 8:37 AM

Merck & Co. (NYSE: MRK) and Eisai announced that their Phase 3 LITESPARK-012 trial evaluating combination treatments for advanced renal ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found